Sabitlenmiş Tweet
Let’s Fight Bladder Cancer, Scotland! @BladderCancerUK @NHS_Lothian @NHS_HS #BladderCancer #BladderCancerAware
English
Prof Param Mariappan FRCS(Urol), PhD
2.8K posts
Prof Param Mariappan FRCS(Urol), PhD
@ParamMariappan
Consultant Urological Surgeon | Director Edinburgh Bladder Cancer Surgery @EdinSurg_BC | @Uroweb Bladder Cancer Guideline panels | Golfer. Views my own
Edinburgh, United Kingdom Katılım Nisan 2019
959 Takip Edilen1.4K Takipçiler
The most important step at the beginning of almost every #BladderCancer patient's pathway.
Regardless of technique, it is vital to deliver the #TURBT as a package.
@UroDocAsh
#IBCG26
#EAU26
#BAUS26
#UroSoMe
Ashish M. Kamat, MD, MBBS@UroDocAsh
Couldn’t agree more! This is why the @IBCG_BladderCA will make this one of the focus topics of our retreat this year, #IBCG26 My prior comments here (some may call it a rant!) 🤷🏻♂️ x.com/urodocash/stat… @UrogerliMD @JoshMeeks @siadaneshmand @JimCatto @RobertoContieri @paolo_gontero @ParamMariappan @joanfundi @jteoh_hk @spsutkaMD @Uromigos @LauraBukavinaMD @WesKassouf @drgaganprakash @SUO_YUO @veerukasi #EAU26
English
@EAUYAUrology @MaximeValle5 @danieleamparore @EnricoCheccucci @mwvetterlein @GMarra_MD @amorgado4 @BenjaminPradere @AngeloTerrito Keep inspiring - well done, everyone! 🌟
English
@shilpaonc @scserendipity1 @UroDocAsh @EUplatinum @EurUrolOncol @Albert0Briganti @montypal @carme_mir1 @spsutkaMD @LauraBukavinaMD Many congratulations Ashish! 👏🏾
English
Congrats @UroDocAsh on receiving the Platinum Award 2026 @EUplatinum @EurUrolOncol for your leadership & being a source of inspiration! @Albert0Briganti
@montypal @carme_mir1
English
@UroDocAsh @brookmans76 @shilpaonc @EUplatinum @EurUrolOncol @IBCG_BladderCA @ClevelandClinic Many congratulations Shilpa - so well deserved indeed !
English
Congratulations to superstar @shilpaonc on receiving the ‘Medical Oncologist Ambassador Award’ for all her work in supporting bladder cancer efforts at @EUplatinum @EurUrolOncol 🥇⭐️👏 #EAU26 @IBCG_BladderCA @ClevelandClinic
English
Prof Param Mariappan FRCS(Urol), PhD retweetledi
Join us tomorrow - Orange Area eURO Auditorium 2
Common problems and controversies in bladder cancer: Rapid-fire debates! with
@NehaVapiwala @ParamMariappan @LAUrology_NL @achoud72 @Prof_Nick_James @DrSpratticus @siadaneshmand @MRoupret @bbmdmsk @joanfundi @LauraBukavinaMD @UroMoschini @jteoh_hk @paolo_gontero @BenjaminPradere @BogdanaSchmidt @MattGalsky @tompowles1 #UroTwitter #BladderCancer #EAU26
Ashish M. Kamat, MD, MBBS@UroDocAsh
As we wrap a whirlwind of data in bladder cancer at #GU26, wishing everyone safe travels home. Rest up - London and #EAU26 are just around the corner! I'm especially excited to once again lead the "Common Problems and Controversies in Bladder Cancer: Rapid-fire Debates." Friday 13 March 10:45 - 12:15 We’ve designed this session to cut through the noise - no long lectures - just leading experts, opposing viewpoints, and the direct clinical insights you need for daily practice. It remains one of the most anticipated highlights of the meeting for a reason!
English
Prof Param Mariappan FRCS(Urol), PhD retweetledi
Efficacy means nothing if we can't get our patients to finish the course!🏁✅
Looking forward to discussing strategies to reduce toxicity, improve patient adherence, decrease dropout rates, and improve efficacy of intravesical BCG 💫
#EAU26 @ParamMariappan @niyatilobo @chats69 @IBCG_BladderCA @WorldBladderCan @UroToday #BladderCancer @UrogerliMD @MargoWickersham
English
@paolo_gontero @jteoh_hk @carme_mir1 @LAUrology_NL @ParamMariappan @MRoupret @joanfundi @DrShariat @UroMoschini @UrogerliMD @shilpaonc Poll #3: High-risk BCG naïve NMIBC: BCG + IO – Bold new standard or overreach?
@paolo_gontero @jteoh_hk @carme_mir1 @LAUrology_NL @MRoupret @joanfundi
@shilpaonc @AndreaNecchi @SpiessPhilippe @AlisonBirtle
#EAU26 #BladderCancer
Suomi
As in prior years, we will again run a series of live polls tied to the Rapid Fire Debate session at #EAU26.
There are no right answers; only your honest perspective. Your vote and comments will help drive the discussion, during the new “Presidential Debate” format introduced by @MaartenAlbersen
#UroTwitter #BladderCancer #EAU26 #GU26
Ashish M. Kamat, MD, MBBS@UroDocAsh
As we wrap a whirlwind of data in bladder cancer at #GU26, wishing everyone safe travels home. Rest up - London and #EAU26 are just around the corner! I'm especially excited to once again lead the "Common Problems and Controversies in Bladder Cancer: Rapid-fire Debates." Friday 13 March 10:45 - 12:15 We’ve designed this session to cut through the noise - no long lectures - just leading experts, opposing viewpoints, and the direct clinical insights you need for daily practice. It remains one of the most anticipated highlights of the meeting for a reason!
English
English
It’s disappointing to me that TURBT continues to be dismissed as a “low-priority” procedure in so many training programs.
This single step defines the entire course for a bladder cancer patient. Accurate diagnosis, precise staging, and the choice of therapy all hinge on a high quality TURBT.
And the “advanced genomic analysis and molecular profiling” these same programs love to promote? It all begins with adequate, high-quality tissue obtained through a TURBT.
Yet incomplete resections leave behind residual tumor in up to 78% of cases at restaging, leading to higher recurrence rates and unnecessary progression.
If we are serious about improving outcomes in NMIBC - and even MIBC - we must treat TURBT with the respect it deserves: structured, deliberate training curricula, hands-on attending involvement, and real performance metrics.
This is why the @IBCG_BladderCA will make this one of the focus topics of our retreat this year, #IBCG26
@UrogerliMD @JoshMeeks @bbmdmsk @siadaneshmand @RobertoContieri @paolo_gontero @ParamMariappan @joanfundi @jteoh_hk @spsutkaMD @WorldBladderCan @BladderCancerUS @drgaganprakash @SUO_YUO @veerukasi
English
@UroDocAsh 💯 agree. It’s vital to Get It Right First Time with the initial resection & diagnosis to reliably determine treated biological potential before any treatment, including doing nothing but surveillance.
#GIRFT
#RealisticMedicine
English
Important randomized data (JCOG1019) suggesting that in carefully selected HG T1 patients with a negative re-TUR, active surveillance may achieve comparable oncologic outcomes to BCG, with less toxicity.
Encouraging signal - especially in the era of BCG constraints
That said, selection is everything. This is not a broad replacement for BCG, but a potential option for a very defined, well-counseled group under close follow-up.
As always in #BladderCancer cancer: biology, quality of resection, and vigilance matter.
@IBCG_BladderCA @UrogerliMD @MaxKates @tompowles1 @MRoupret @JoshMeeks @joanfundi @AndreaNecchi
European Urology@EUplatinum
📢 New publication in European Urology We are pleased to highlight a new study published in European Urology, titled "Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial". 👏 Congratulations to Hiroshi Kitamura et al. on this excellent contribution, together with all co-authors. 🔗 Read the full article here: 👉 lnkd.in/ePEvrQDY #EuropeanUrology #Urology #UroOncology #Research #MedicalResearch #AcademicUrology
English
Prof Param Mariappan FRCS(Urol), PhD retweetledi
🚨JUST RELEASED!
📺Watch the discussion with @UroDocAsh on our publication at @EurUrolOncol, posted by @urotoday
🎙️We speak about the definition of cure in #bladdercancer
🔗tinyurl.com/mwb972az
Félix Guerrero-Ramos@DrFelixGuerrero
❓How to define #cure in localized #bladdercancer? 🥸Check out our #systematicreview on this hot topic just published in @EurUrolOncol 🔗t.ly/tz16i @dralvaropinto @H12Octubre @bvh12o @Uroweb @GuardConsortium @IBCG_BladderCA @UroDocAsh @MRoupret @jteoh_hk @CANVES_ES
Cota, Colombia 🇨🇴 English
English
@ParamMariappan Congrats Param and also supports our prior @JAMA_current work by @KKBree showing substantial costs of surveillance that can be safely omitted in these patients. 👍 jamanetwork.com/journals/jaman…
English
20 years ago we suggested ceasing surveillance in G1Ta #BladderCancer after 5 recurrence-free years: pubmed.ncbi.nlm.nih.gov/15758711/
From our recent work, further de-intensifiction of surveillance in low risk patients is feasible. authors.elsevier.com/a/1mHug9Cfw03S…
English
@DrFelixGuerrero Many thanks Felix 🙏🏽
English
@ParamMariappan Really beautiful report! Congrats!
English
Prof Param Mariappan FRCS(Urol), PhD retweetledi
Very important study. Most NMIBCrelated costs are driven by overtreatment and oversurveillance in LR disease. Kudos to @ParamMariappan for this key step toward deintensifying FU in LR NMIBC. Together with treatment deintensification, it can rationalize costs and improve pts QoL
Prof Param Mariappan FRCS(Urol), PhD@ParamMariappan
20 years ago we suggested ceasing surveillance in G1Ta #BladderCancer after 5 recurrence-free years: pubmed.ncbi.nlm.nih.gov/15758711/ From our recent work, further de-intensifiction of surveillance in low risk patients is feasible. authors.elsevier.com/a/1mHug9Cfw03S…
English
Prof Param Mariappan FRCS(Urol), PhD retweetledi
Since launching in April we have delivered ~250 Teal Boxes of Love wrapped in care, compassion and community with the powerful message: 'You are not alone' ❤️
Let's ask🎙️Dr. Aparna Kamat what she thinks about the TBOLs.
🙏🏼for making this dream project a statement to Ovarcome🩵!
English
@DrFelixGuerrero @WghLothian @EdinSurg_BC @JHartBrooke @TanyaLORD1 @NHSScotland @NHS_Lothian @NUCLEIX2 @PhotocureASA @KARLSTORZUro @mirrorsmed So kind - may thanks, my friend 🙏🏽
English
@ParamMariappan @WghLothian @EdinSurg_BC @JHartBrooke @TanyaLORD1 @NHSScotland @NHS_Lothian @NUCLEIX2 @PhotocureASA @KARLSTORZUro I already used your paper for one of my slides in #BLADDR25, just the day after it was published. Congrats for such a beautiful and useful study! @mirrorsmed
English
Pleased to share our work on combining Bladder Epicheck biomarker and Photodynamic Diagnosis to improve the effectiveness in detecting high grade/ cis recurrence during surveillance of HR-NMIBC patients.
pubmed.ncbi.nlm.nih.gov/41314886/
@WghLothian @EdinSurg_BC
English
@SWilliams_MD @WghLothian @EdinSurg_BC @JHartBrooke @TanyaLORD1 @NHSScotland @NHS_Lothian @NUCLEIX2 @PhotocureASA @KARLSTORZUro Many thanks Steve 🙏🏽
English
@ParamMariappan @WghLothian @EdinSurg_BC @JHartBrooke @TanyaLORD1 @NHSScotland @NHS_Lothian @NUCLEIX2 @PhotocureASA @KARLSTORZUro Congrats Param and team! 👍
English